Gemtuzumab ozogamicin - Wikipedia
Gemtuzumab ozogamicin is a recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ antibody hP67.6) covalently attached to the cytotoxic antitumor antibiotic calicheamicin (N-acetyl-γ-calicheamicin) payload via a bifunctional linker (4-(4-acetylphenoxy)butanoic acid).
MYLOTARG™ (gemtuzumab ozogamicin) | Pfizer Medical …
MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.
Gemtuzumab ozogamicin Uses, Side Effects & Warnings - Drugs.com
2024年9月13日 · Gemtuzumab ozogamicin is used to treat a certain type (CD33-positive) of newly-diagnosed acute myeloid leukemia in adults and children at least 1 month old. Gemtuzumab ozogamicin is also used to treat CD33-positive acute myeloid leukemia after other treatments did not work or have stopped working in adults and children at least 2 years old.
FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML
On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia...
Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, …
Gemtuzumab ozogamicin (GO) is one of the most thoroughly studied molecularly targeted therapies in adults. GO is a monoclonal antibody against CD33 IgG4 linked to the cytotoxic drug calicheamicin DMH.
Gemtuzumab Ozogamicin for Treatment of Acute Myeloid …
Gemtuzumab ozogamicin (GO) is the only new agent approved for treatment of the vast majority of AML patients, including ND-AML and RR-AML disease in adults and RR-AML in pediatric patients. Of note, these indications for GO expand upon the previous US approval of GO, which was limited only to adult patients with RR-AML in 2000.
MYLOTARG™ (gemtuzumab ozogamicin) Clinical Pharmacology
Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 antigen. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker.
Update on the role of gemtuzumab-ozogamicin in the treatment …
Gemtuzumab-ozogamicin (GO) is an ADC in which a monoclonal antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO is the first (and at the time of this writing, the only) ADC approved for the treatment of patients with AML.
Gemtuzumab Ozogamicin - NCI - National Cancer Institute
Gemtuzumab ozogamicin is approved to treat: Acute myeloid leukemia that is CD33 positive . It is used in adults and children aged 1 month and older with newly- diagnosed disease.
FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen...